Search Result

Results for "

decline

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (4) 5-HT Receptor (3) Adrenergic Receptor (1) AMPK (2) Amyloid-β (2) Apoptosis (3) Atg4 (1) ATP Synthase (1) Autophagy (1) Cathepsin (1) Cholinesterase (ChE) (4) COX (2) Endogenous Metabolite (3) Keap1-Nrf2 (1) LPL Receptor (2) Monoamine Oxidase (3) NOD-like Receptor (NLR) (1) Oxidative Phosphorylation (2) Parasite (1) Phospholipase (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (1) PPAR (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (4) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (17)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W106057

11β-HSD1-IN-7	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-7 (compound c10a) is a 11β‑HSD1 inhibitor with an IC₅₀ value of 1.9 μM for human 11β‑HSD1. 11β-HSD1-IN-7 can be used for the research of diabetes and cognitive decline .

HY-W129359

11β-HSD1-IN-8	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-8 (compound c6a) is a 11β‑HSD1 inhibitor with an IC₅₀ value of 2.3 μM for human 11β‑HSD1. 11β-HSD1-IN-8 can be used for the research of diabetes and cognitive decline .

HY-110291

A-971432	LPL Receptor	Neurological Disease
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC₅₀s of .362, >10, 0.006 μM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .

HY-165514A

Nafimidone hydrochloride	Cholinesterase (ChE)	Neurological Disease
Nafimidone hydrochloride is an anticonvulsant which inhibits cholinesterases, protects neurons, and ameliorates cognitive decline. Nafimidone can be utilized in epilepsy research .

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-14156

11β-HSD1-IN-15	11β-HSD	Metabolic Disease
11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes .

HY-151627

11β-HSD1-IN-11	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-11 (Compound c1a) is a competitive 11β-HSD1 inhibitor with IC₅₀s of 0.34 μM and 0.13 μM against rat and human 11β-HSD1, respectively .

HY-113448

CE(20:3(8Z,11Z,14Z)) 20:3 (8Z,11Z,14Z) CE; 20:3 n-6 CE; 20:3 (8Z,11Z,14Z) Cholesterol Ester	Endogenous Metabolite	Cardiovascular Disease
Cholesteryl homo-γ-linolenate is a cholesterol ester. It accumulates in the adrenal gland of rabbits fed a diet high in linolenic acid.1 Levels of cholesteryl homo-γ-linolenate are decreased and positively correlate with cognitive decline in HIV-infected humans.

HY-117255

ZM260384	Potassium Channel	Others
ZM260384 is a K_ATP channel opener that accelerates metabolism and inhibits the decline of guinea pig isolated diaphragm function, thereby affecting muscle contraction. ZM260384 can be used to study muscle function under hypoxic conditions .

HY-101339

(R)-RS 56812	Others	Others
(R)-RS 56812 is a 5-HT3 receptor antagonist that enhances performance in monkeys on a delayed matching task. The (R) isomer produces more systematic improvements than the (S) isomer and has potential inhibitory effects in diseases involving cognitive decline.

HY-101339A

(R)-RS 56812 hydrochloride	Others	Others
(R)-RS 56812 hydrochloride is a 5-HT3 receptor antagonist that enhances performance in monkeys on a delayed matching task. The (R) isomer produces more systematic improvements than the (S) isomer and has potential inhibitory effects in diseases involving cognitive decline.

HY-B0193

Prazosin Maximum Cited Publications 12 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Prazosin is an α-adrenergic receptor antagonist. Prazosin can reduce inflammation, relieve anxiety, alleviate panic, prevent memory decline, and modulate the pain-relieving effects of opioids. Prazosin can be used in the study of hypertension and Alzheimer’s disease .

HY-N5130

Effusol	Others	Neurological Disease
Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC₅₀ values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline .

HY-163646

(Rac)-TZ3O	Cholinesterase (ChE)	Neurological Disease
(Rac)-TZ3O is the (Rac) isomer of TZ3O. TZ3O is an anticholinergic compound with neuroprotective activity. TZ3O improves memory impairment and cognitive decline in a scopolamine-induced Alzheimer's disease rat model and can be used in the study of Alzheimer's disease.

HY-155822

TZ3O	Cholinesterase (ChE)	Neurological Disease
TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .

HY-P990110

Lecanemab (Mouse IGG2a) Mab158	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

HY-162613

ASM-IN-2	Phospholipase	Neurological Disease
ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC₅₀ value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs .

HY-118960

BMS-199264 hydrochloride	ATP Synthase	Cardiovascular Disease
BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC₅₀=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .

HY-119035

R-75317	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .

HY-17629

Dapansutrile 2 Publications Verification OLT1177	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Dapansutrile is a potent, orally active and selective NLRP3 inflammasome inhibitor. Dapansutrile has anti-inflammatory activity and decreases immune factor levels. Dapansutrile can be used for research of inflammatory diseases .

HY-103142

AS19	5-HT Receptor	Neurological Disease
AS19 is a potent, selective 5-HT₇ receptor agonist with an IC₅₀ value of 0.83 nM and a K_i of 0.6 nM. AS19 is selective for 5-HT₇ over 5-HT_1A, 5-HT_1B, 5-HT_1D, and 5-HT_5A receptors (K_is = 89.7 nM, 490 nM, 6.6 nM and 98.5 nM, respectively). AS19 enhances memory consolidation and reverses Scopolamine- or Dizocilpine-induced amnesia .

HY-N2292

Kinsenoside 1 Publications Verification	Keap1-Nrf2 Apoptosis	Inflammation/Immunology
Kinsenoside is the main active ingredient of the genus plant, and has various biological activities. Kinsenoside and Nrf2 depend on the protection of nuclear cells (NPCs), which significantly reduces their ability to survive. Kinsenoside Active NPC Medium AKT-ERK1/2-Nrf2 Signal passage, Prevent physical decline, aging, harmonious physical function impairment. Kinsenoside can improve the puncture guide model for intermediate vertebral wall discharge (IDD).

HY-144636

Atg4B-IN-2	Atg4 Cathepsin Phospholipase Autophagy	Cancer
Atg4B-IN-2 is a potent competitive Atg4B inhibitor with K_i value of 3.1 μM, also possesses declining PLA₂ inhibitory potency, IC₅₀s of 11 μM and 3.5 μM for Atg4B and PLA₂, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition .

HY-116535A

DL-threo-PPMP hydrochloride	Parasite	Infection
DL-threo-PPMP hydrochloride is an inhibitor of sphingosine synthetase in Plasmodium falciparum. DL-threo-PPMP hydrochloride inhibits the activity of sphingosine synthetase (sphingosine synthetase) by binding to a substrate that mimics sphingosine. This inhibition leads to a rapid decline in sensitive sphingomyelin synthase (SSS) activity, selectively disrupting the interconnected tubular network of TVM in the cytoplasm of the host cell, and this inhibition also blocks the proliferation of the parasite. DL-threo-PPMP hydrochloride can be used in the study of malaria parasite biology and the search for new antimalarial strategies .

HY-N0667R

L-Asparagine (Standard)	Endogenous Metabolite	Neurological Disease Cancer
L-Asparagine (Standard) is the analytical standard of L-Asparagine. This product is intended for research and analytical applications. L-Asparagine ((-)-Asparagine) is a non-essential amino acid involved in the metabolic control of nerve and brain tissue cell function. L-Asparagine has antitumor activity . In Vitro:L-Asparagine (0.03 mM) can reverse the proliferation decline of six human cancer cells induced by ASNS siRNA knockdown . L-Asparagine (10 mM, 4 h) can stimulate ODC activity and proliferation in IPEC-J2 cells .

HY-N2435

[8]-Shogaol 1 Publications Verification	COX Apoptosis	Cancer
[8]-Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. [8]-Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

HY-136093A

Lixumistat acetate IM156; HL156A; HL271 acetate	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model . Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-155330

PZ-1922	5-HT Receptor Monoamine Oxidase	Neurological Disease
PZ-1922 (Compound 16) is a BBB-penetrable 5-HT6R/5-HT3R antagonist (K_i: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 reversibly inhibits MAO-B (pIC₅₀: 8.93). PZ-1922 reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 prevents Aβ-induced memory decline in the T-maze test .

HY-W440983

SDPC PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine	PPAR	Cardiovascular Disease Cancer
SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .

HY-136093

Lixumistat hydrochloride HL271; IM156 hydrochloride; HL156A hydrochloride	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model . Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-155330A

PZ-1922 free base	5-HT Receptor Monoamine Oxidase	Neurological Disease
PZ-1922 free base is a BBB-penetrable 5-HT6R/5-HT3R antagonist (K_i: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 free base reversibly inhibits MAO-B (pIC₅₀: 8.93). PZ-1922 free base reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 free base prevents Aβ-induced memory decline in the T-maze test .

HY-118243

KMS88009	Amyloid-β	Others
KMS88009 is a potent small molecule that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive behavior when used preventively and reversing cognitive behavior decline when used therapeutically. Oral administration of KMS88009 around the onset of Alzheimer's disease symptoms significantly reduced the assembly of amyloid-β oligomers and improved cognitive behavior in the APP/PS1 double transgenic mouse model. This unique dual mode of action suggests that KMS88009 may be a powerful therapeutic candidate for the treatment of Alzheimer's disease. In an evaluation, the physicochemical properties, pharmacokinetics and toxicity of this anti-amyloidogenic small molecule KMS88009 were studied, as well as post-mortem analysis of APP/PS1 TG mice after behavioral testing.

HY-N2435R

[8]-Shogaol (Standard)	COX Apoptosis	Cancer
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

HY-158978

Multitarget AD inhibitor-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC₅₀=0.14 μM), butyrylcholinesterase (BChE, IC₅₀=11.6 μM), monoamine oxidase B (MAO B, IC₅₀=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library	1,587 compounds
Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc. MCE offers a unique collection of 1,587 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Anti-Alzheimer's Disease Compound Library

1,587 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1,587 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L034

Anti-Aging Compound Library	5,119 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 5,119 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

5,119 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 5,119 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Target	Research Area